Brandenburg Kapital - News about Lindis Blood Care GmbH

Hennigsdorf – January 2024. The Lindis Blood Care GmbH announced in December 2023 that the last patient in the clinical study REMOVE has also been treated successfully with CATUVAB®. The medical technology company aims to set a new standard for the removal of tumor cells from shed blood during oncological surgery.

Their technology enables clinicians to safely re-transfuse the patient’s own blood during high blood loss surgery, instead of relying on donor blood.

Top line results are expected in Q1 2024. Based on the expected positive study results, Lindis Blood Care will apply for approval of CATUVAB® in the EU and US.

REMOVE is an open-label multicenter clinical study, which enrolled 130 patients, and is one of the largest studies in this indication.

In light of the risks attached with the usage of donor blood and its scarcity, Lindis Blood Care’s approach provides a significant benefit to patients while at the same time preserving valuable donor blood.

Read the full press release here:

https://www.lindis-bloodcare.com/news/lifesciences-2/

About Lindis Blood Care

Lindis Blood Care is a Hennigsdorf-based medical technology company developing the medical product CATUVAB® for the removal of tumor cells from patient blood during oncological surgery. The re-transfusion of surgical shed blood is generally used today in non-oncological procedures. CATUVAB® is designed to expand this approach to cancer patients.

Brandenburg Kapital, the venture capital arm of the investment bank of the state of Brandenburg, is one of the lead investors of Lindis Blood Care and congratulates the company to this success.

Further information on www.lindis-bloodcare.com and www.brandenburg-kapital.de